Drug Profile
KRN 633
Alternative Names: KRN-633Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Kirin Brewery
- Developer Kirin Holdings Company
- Class Amides; Antineoplastics; Quinazolines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in Japan (PO)
- 20 Nov 2008 Asked Sue to map it with Drug classes: Quinazolines and Amides in Thes
- 24 Oct 2008 Phase-I clinical trials in Solid tumours in Japan (PO)